LYEL · Bull vs Bear

The case for and the case against Lyell Immunopharma, Inc., each point drawn from public SEC filings — who’s buying, the red flags, and the health score. No opinion, no price call. Read both sides, then pick yours.

the bull case // 1

Insiders are buying

2 open-market insider purchases on recent Form 4s — company officers and directors putting their own money in.

SEC Form 4 →

the bear case // 4

Bankruptcy-risk zone

Altman Z-Score is in the distress zone (-6.56).

SEC filing ↗

Active dilution shelf

An effective S-3 shelf with 1 prospectus filing(s) in 12 months — shares may be getting sold into the market.

SEC filing ↗

Weak fundamentals

Piotroski F-Score of 1/9 — most quality checks are failing.

SEC filing ↗

Weak price momentum

-37.3% vs 200-day

SEC XBRL

where do you land on LYEL?

Bull Bear

Saved on this device. Your call, from the evidence above — not a recommendation.

Educational only — not financial adviceand never a recommendation to buy or sell. Both sides are built from public SEC filings (Form 4, STOCK Act, 13F, XBRL financials), which lag 40–90 days; absence of a red flag is not a clean bill of health.